Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Update

Alzamend Neuro, Inc. (NASDAQ:ALZN) saw a significant drop in short interest during the month of April. As of April 15th, there was short interest totalling 223,800 shares, a drop of 37.6% from the March 31st total of 358,600 shares. Based on an average daily trading volume, of 368,000 shares, the days-to-cover ratio is currently 0.6 days. Approximately 3.5% of the company’s shares are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Alzamend Neuro stock. Citadel Advisors LLC acquired a new stake in Alzamend Neuro, Inc. (NASDAQ:ALZN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 30,638 shares of the company’s stock, valued at approximately $36,000. Citadel Advisors LLC owned approximately 0.56% of Alzamend Neuro as of its most recent filing with the Securities and Exchange Commission. 49.61% of the stock is owned by hedge funds and other institutional investors.

Alzamend Neuro Trading Up 0.4 %

Shares of Alzamend Neuro stock opened at $0.66 on Wednesday. The firm’s 50-day moving average is $0.83 and its two-hundred day moving average is $1.13. Alzamend Neuro has a 1 year low of $0.64 and a 1 year high of $15.06.

Alzamend Neuro (NASDAQ:ALZN) last released its quarterly earnings results on Monday, March 10th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.10. Equities analysts expect that Alzamend Neuro will post -1.68 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Ascendiant Capital Markets decreased their price target on Alzamend Neuro from $32.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, March 17th.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.